650
Views
6
CrossRef citations to date
0
Altmetric
Original Research

Medication Profile and Treatment Cost Estimation Among Outpatients with Schizophrenia, Bipolar Disorder, Depression, and Anxiety Disorders in Indonesia

ORCID Icon, ORCID Icon, , , , , & show all
Pages 815-828 | Published online: 26 Mar 2020

References

  • WHO. Mental disorders affect one in four people; 2001 Available from: https://www.who.int/whr/2001/media_centre/press_release/en/. Accessed 1031, 2019.
  • World Health Organization. Mental disorders; 2018 Available from: https://www.who.int/news-room/fact-sheets/detail/mental-disorders. Accessed 1031, 2019.
  • Statistics Indonesia. Population 15 years of age and over by age group and type of activity during the previous week, 2008–2018; 2019 Available from: https://www.bps.go.id/statictable/2016/04/04/1904/penduduk-berumur-15-tahun-ke-atas-menurut-golongan-umur-dan-jenis-kegiatan-selama-seminggu-yang-lalu-2008—2018.html. Accessed 1125, 2019.
  • SI BPS. Statistical Yearbook of Indonesia. Sub-directorate of Statistical Compilation and Publication ed.; 2018.
  • Ministry of Health Republic of Indonesia. National report basic health research 2018; 2018 Available from: http://labmandat.litbang.depkes.go.id/images/download/laporan/RKD/2018/Laporan_Nasional_RKD2018_FINAL.pdf. Accessed 312, 2020.
  • DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. Pharmacotherapy: A Pathophysiologic Approach. 8th ed. McGraw Hill; 2011.
  • Work Group on Schizophrenia. Practice Guideline for the Treatment of Patients with Schizophrenia. 2nd ed. American Psychiatric Association; 2010.
  • Miyamoto S, Miyake N, Jarskog LF, Fleischhacker WW, Lieberman JA. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol Psychiatry. 2012;17(12):1206–1227. doi:10.1038/mp.2012.4722584864
  • Ganguly P, Soliman A, Moustafa AA. Holistic management of schizophrenia symptoms using pharmacological and non-pharmacological treatment. Front Public Heal. 2018;6(166):1–9. doi:10.3389/fpubh.2018.00166
  • Vieta E. Managing Bipolar Disorder in Clinical Practice: Third Edition; 2013. doi:10.1007/978-1-908517-94-4.
  • Geddes JR, Miklowitz DJ. Treatment of bipolar disorder. Lancet. 2013;381(9878):1672–1682. doi:10.1016/S0140-6736(13)60857-023663953
  • Grande I, De Arce R, Jiménez-Arriero MÁ, et al. Patterns of pharmacological maintenance treatment in a community mental health services bipolar disorder cohort study (SIN-DEPRES). Int J Neuropsychopharmacol. 2013;16(3):513–523. doi:10.1017/S146114571200040522717099
  • Chisholm-Burns MA, Schwinghammer TL, Well BG, Malone PA, Kolesar JM, DiPiro JT. Pharmacotherapy Principles & Practice. 4th ed. McGraw Hill Education; 2016.
  • Mirabel-Sarron C, Giachetti R. Non pharmacological treatment for bipolar disorder. Encephale. 2012;38(4). doi:10.1016/S0013-7006(12)70094-5
  • Kumar KPS, Srivastava S, Paswan S, Dutta AS. Depression - symptoms, causes, medications and therapies. Pharm Innovation. 2012;1(3):37.
  • Spijker J, Van Straten A, Bockting CLH, Meeuwissen JAC, Van Balkom AJLM. Psychotherapy, antidepressants, and their combination for chronic major depressive disorder: a systematic review. Can J Psychiatry. 2013;58(7):386–392. doi:10.1177/07067437130580070323870720
  • Wang S-M, Han C, Bahk W-M, et al. Addressing the side effects of contemporary antidepressant drugs: a comprehensive review. Chonnam Med J. 2018;54(2):101. doi:10.4068/cmj.2018.54.2.10129854675
  • Wells BG, DiPiro JT, Schwinghammer TL, Dipiro CV. Pharmacotherapy Handbook. 9th ed. New York: McGraw Hill Education; 2015.
  • Gartlehner G, Wagner G, Matyas N, et al. Pharmacological and non-pharmacological treatments for major depressive disorder: review of systematic reviews. BMJ Open. 2017;7(6):e014912. doi:10.1136/bmjopen-2016-014912
  • Park S-C, Oh HS, Oh D-H, et al. Evidence-based, non-pharmacological treatment guideline for depression in Korea. J Korean Med Sci. 2014;29(1):12–22. doi:10.3346/jkms.2014.29.1.1224431900
  • Victoria Institute of Strategic Economic Studies. The economic cost of serious mental illness and comorbidities in Australia and New Zealand. R Aust New Zeal Coll Psychiatr. 2016:1–48. Available from: https://www.ranzcp.org/Files/Publications/RANZCP-Serious-Mental-Illness.aspx. Accessed March 12, 2020.
  • Gariepy G, Nitka D, Schmitz N. The association between obesity and anxiety disorders in the population: A systematic review and meta-analysis. Int J Obes. 2010;34(3):407–419. doi:10.1038/ijo.2009.252
  • Reinhold JA, Mandos LA, Rickels K, Lohoff FW. Pharmacological treatment of generalized anxiety disorder. Expert Opin Pharmacother. 2011;12(16):2457–2467. doi:10.1517/14656566.2011.61849621950420
  • Lampe L. Drug treatment for anxiety. Aust Prescr. 2013;36(6):186–189. doi:10.18773/austprescr.2013.076
  • Strawn JR, Geracioti L, Rajdev N, Clemenza K, Levine A. Pharmacotherapy for generalized anxiety disorder in adults and pediatric patients: an evidence-based treatment review. Expert Opin Pharmacother. 2018;19(10):1057–1070. doi:10.1080/14656566.2018.149196630056792
  • Bystritsky A, Khalsa SS, Cameron ME, Schiffman J. Current diagnosis and treatment of anxiety disorder. Pharm Ther. 2013;38(1):30–57.
  • Combs H, Markman J. Anxiety disorders in primary care. Med Clin North Am. 2014;98(5):1007–1023. doi:10.1016/j.mcna.2014.06.00325134870
  • Cottraux J. Nonpharmacological treatments for anxiety disorders. Dialogues Clin Neurosci. 2002;4(3):305–319.22034140
  • Jo C. Cost-of-illness studies: concepts, scopes, and methods. Clin Mol Hepatol. 2014;20(4):327–337. doi:10.3350/cmh.2014.20.4.32725548737
  • Trautmann S, Rehm J, Wittchen H. The economic costs of mental disorders. EMBO Rep. 2016;17(9):1245–1249. doi:10.15252/embr.20164295127491723
  • Vos T, Barber RM, Bell B, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386(9995):743–800. doi:10.1016/S0140-6736(15)60692-426063472
  • Goetzel RZ, Roemer EC, Holingue C, et al. Mental health in the workplace: a call to action proceedings from the mental health in the workplace-public health summit. J Occup Environ Med. 2018;60(4):322–330. doi:10.1097/JOM.000000000000127129280775
  • Bloom D, Cafero E, Jané-Llopis E, et al. The global economic burden of non-communicable diseases. Geneva: world Economic Forum; 2011 Available from: http://www3.weforum.org/docs/WEF_Harvard_HE_GlobalEconomicBurdenNonCommunicableDiseases_2011.pdf. Accessed 1125, 2019.
  • Mangalore R, Knapp M. Cost of Schizophrenia. J Ment Health Policy Econ. 2007;10(1):23–41.17417045
  • Dilsaver SC. An estimate of the minimum economic burden of bipolar i and II disorders in the United States: 2009. J Affect Disord. 2011;129(1–3):79–83. doi:10.1016/j.jad.2010.08.03020888048
  • Cloutier M, Greene M, Guerin A, Touya M, Wu E. The economic burden of bipolar I disorder in the United States in 2015. J Affect Disord. 2018;226:45–51. doi:10.1016/j.jad.2017.09.01128961441
  • Dieleman JL, Baral R, Birger M, et al. US spending on personal health care and public health, 1996–2013. JAMA. 2016;316(24):2627–2646. doi:10.1001/jama.2016.1688528027366
  • Sado M, Takechi S, Inagaki A. et al. Cost of anxiety disorders in Japan in 2008: a prevalence-based approach. BMC Psychiatry. 2013:13. doi:10.1186/1471-244X-13-338.23297686
  • Okpataku CI, Tawani D, Article O. Psychotropic prescriptions for the treatment of schizophrenia in an outpatient clinic. Trends Psychiatry Psychother. 2017;39(3):165–172. doi:10.1590/2237-6089-2016-008828876362
  • Khan A, Iqbal Z, Sultan SM, Nazar Z, Tariq M. Antipsychotic prescription patterns and treatment costs of schizophrenia in northwestern Pakistan: a one-year observational study. Trop J Pharm Res. 2018;17:339–344.
  • Irene M. A systematic review of instruments to measure depressive symptoms in patients with schizophrenia publisher’ s pdf, also known as version of record publication date. J Affect Disord. 2012;140(1):38–47. doi:10.1016/j.jad.2011.10.01422099566
  • National Collaborating Centre for Mental H. Bipolar Disorder: The NICE Guideline on the Assessment and Management of Bipolar Disorder in Adults, Children and Young People in Primary and Secondary Care. Leicester: The British Psychological Society & The Royal College of Psychiatrists; 2014.
  • Chawla S, Agarwal M, Sharma S, Jiloha RC. Drug utilization study of psychotropic drugs among psychiatric outpatients in a tertiary care hospital. Indian J Pharm Sci. 2017;79(6):1008–1013. doi:10.4172/pharmaceutical-sciences.1000319
  • Holzapfel EM, Szabo CP. Pharmacotherapy prescribing patterns in the treatment of bipolar disorder in a South African outpatient population. Glob Psychiatry. 2018;1(2):39–51. doi:10.2478/gp-2018-0006
  • National Institute for Health and Care Excelence. Bipolar disorder: assessment and management; 2014 Available from: https://www.nice.org.uk/guidance/cg185/chapter/1-Recommendations. Accessed 1125, 2019.
  • Taylor D, Paton C, Kapur S. Prescribing Guidelines in Psychiatry. 11th ed. Wiley-Blackwell; 2012.
  • Turner TL. The use of antipsychotics in maintenance treatment of bipolar disorder. Ment Heal Clin. 2013;2(12):412–415. doi:10.9740/mhc.n155513
  • Rossatria E. Evaluation of Antidepressants Drug Prescribing for Depressed Patients at Pharmacy Installation Outpatient in Regional Hospital Dr. Soehadi Prijonegoro Sragen; 2016.
  • Yuniastuti. Evaluation of Antidepressant Drug for Therapy Patient In Depression Mental Hospital Surakarta 2011–2012; 2013.
  • Ogawa Y, Takeshima N, Hayasaka Y, et al. Antidepressants plus benzodiazepines for adults with major depression. Cochrane Database Syst Rev. 2019;2019(6). doi:10.1002/14651858.CD001026.pub2
  • Bandelow B, Zohar J, Hollander E, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - First revision. World J Biol Psychiatry. 2008;9(4):248–312. doi:10.1080/1562297080246580718949648
  • Farach FJ, Pruitt LD, Jun JJ, Jerud AB, Zoellner LA, Roy-Byrne PP. Pharmacological treatment of anxiety disorders: current treatments and future directions. J Anxiety Disord. 2012;26(8):833–843. doi:10.1016/j.janxdis.2012.07.00923023162
  • Tanguay Bernard MM, Luc M, Carrier JD, et al. Patterns of benzodiazepines use in primary care adults with anxiety disorders. Heliyon. 2018;4(7). doi:10.1016/j.heliyon.2018.e00688
  • Crocco EA, Jaramillo S, Cruz-Ortiz C, Camfield K. Pharmacological management of anxiety disorders in the elderly. Curr Treat Options Psychiatry. 2017;4(1):33–46. doi:10.1007/s40501-017-0102-428948135
  • Ellen S, Selzer R, Norman T, Blashki G. Depression and anxiety: pharmacological treatment in general practice. Aust Fam Physician. 2007;36(4):222–228.17392933
  • Ye W. Health care resource use and direct medical costs for patients with schizophrenia in Tianjin, People’ s Republic of China. Neuropsychiatr Dis Treat. 2015;11:983–990.25897235
  • Oloniniyi IO, Akinsulore A, ALoba OO, Mapayi BM, Oginni OA, Makanjuola R. Economic cost of schizophrenia in a Nigerian Teaching Hospital. J Neurosci Rural Pract. 2019;10(1):39–47. doi:10.4103/jnrp.jnrp_210_1830765969
  • Chong HY, Teoh SL, Wu DB-C, Kotirum S, Chiou C-F, Chaiyakunapruk N. Global economic burden of schizophrenia: a systematic review. Neuropsychiatr Dis Treat. 2016;12:357–373. doi:10.2147/NDT.S9664926937191
  • Sarkar S, Mathan K, Sakey S, Shaik S, Subramanian K, Kattimani S. Cost-of-treatment of clinically stable severe mental lilnesses in India. Indian J Soc Psychiatry. 2017;33(3):262. doi:10.4103/0971-9962.214600
  • Cloutier M, Greene M, Guerin A, Touya M, Wu E. The economic burden of bipolar I disorder in the United States in 2015. J Affect Disord. 2018;15(226):45–51. doi:10.1016/j.jad.2017.09.011
  • Okumura Y, Higuchi T. Cost of depression among adults in Japan. Prim Care Companion CNS Disord. 2011;13(3):PCC.10m01082. doi:10.4088/PCC.10m01082
  • Shirneshan E, Bailey J, Relyea G, Franklin BE, Solomon DK, Brown LM. Incremental direct medical expenditures associated with anxiety disorders for the U.S. adult population: evidence from the medical expenditure panel survey. J Anxiety Disord. 2013;27(7):720–727. doi:10.1016/j.janxdis.2013.09.00924135257
  • Ministry of Health Republic Indonesia. Heart disease is the highest cause of death, Ministry of Health reminds the CERDIK; 2017 Available from: https://www.depkes.go.id/article/view/17073100005/penyakit-jantung-penyebab-kematian-tertinggi-kemenkes-ingatkan-cerdik.html. Accessed 1030, 2019.
  • Velligan DI, Sajatovic M, Hatch A, Kramata P, Docherty JP. Why do psychiatric patients stop antipsychotic medication? A systematic review of reasons for nonadherence to medication in patients with serious mental illness. Patient Prefer Adherence. 2017;11:449–468. doi:10.2147/PPA.S12465828424542